Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Sep 22, 2022 10:28am
104 Views
Post# 34978843

RE:RE:Most promising…

RE:RE:Most promising…

Yep, I specifically went looking for new patents last week and found nothing, you're clearly better at this than me.

I guess this explains the timing of the CSC paper to some extent. It's possible there are more revelations about the action of the drugs waiting for IP. At the bottom it also indicates that Chinese IP of the original PDC patent was recently accepted. They're almost wilfully choosing to NOT talk about these little but important successes.

(The IP I'm waiting for is something about exosome, just my pet fantasy. See if you can find that Scarlett)

palinc2000 wrote:

Great find as always Scarlett!
 

 

scarlet1967 wrote:

 

They filed the WO patent in February and it was published this month. Cancer stem cells as per latest research are present in various types of cancers including:

Breast, Colon, Ovary, Pancreas, Prostate, Melanoma, Multiple Myeloma, Non-melanoma skin cancer…

Although this research is early in the process it seems if and when they can duplicate the results in humans it can add significant value to the potential treatment against metastatic cancers.

From the patent application:

 

 

 

“Nearly all current cancer treatments focus on de-bulking tumors without targeting the most dangerous cells in the tumor: cancer stem cells (CSCs). CSCs are responsible for the spread of cancer cells throughout the body, the growth of tumors, cancer’s resistance to chemotherapy, and the recurrence of tumors after treatment or surgical removal, notably through their ability to arrest in the GO phase, giving rise to new tumors. Because current treatments do not target the CSC population, they frequently lead to the rise of resistant tumors and continued cancer spread. Therefore, CSCs could be considered the most promising targets for cancer treatment. There is thus a need for the development of strategies for the treatment of cancer, and more particularly cancers associated with CSCs, for example to overcome tumor resistance to cancer therapy, and prevent/treat cancer relapse and improve survival in cancer patients.”

 

https://patents.google.com/patent/WO2022178634A1/en

 





<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse